Who is sponsoring NCT07033585?

NCT07033585 is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

What drugs are being tested in NCT07033585?

Interventions in NCT07033585: Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes.

What condition does NCT07033585 study?

NCT07033585 studies Type 2 Diabetes.

Is NCT07033585 still recruiting?

NCT07033585 is currently active, enrolled. Last updated 11 July 2025.

Last reviewed 2025-07-11 · How we verify

NCT07033585: GD-T2D

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Active, enrolled Phase 2, PHASE3 Last updated 11 July 2025

What this trial tests

Phase 2, PHASE3 trial testing Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes in Type 2 Diabetes in 600 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 June 2025

Primary endpoint
18 October 2026

28 November 2026

Quick facts

Lead sponsor	Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase	Phase 2, PHASE3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	health services research
Enrollment	600
Start date	15 June 2025
Primary completion	18 October 2026
Estimated completion	28 November 2026
Sites	1 location across United States

Drugs / interventions tested

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes — full drug profile →
China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — full company profile →

Who can join

Adults 24 to 64, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair trials

Trials by the same sponsor.

NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07182838 — Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT07145333 — Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT01064466 — Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT06062810 — Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07033585 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Last refreshed: 11 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07033585.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing